Bijal Shah, MD, on AUTO1 in R/R B-Cell ALL and the FELIX Trial
Shah explained that the trial is unique due to its inclusion of patients with MRD–positive B-ALL.
Brexucabtagene Autoleucel in R/R Mantle Cell Lymphoma
Experts discussed the ZUMA-2 clinical trial of brexucabtagene autoleucel.
The Need for Academic and Community Collaboration With CAR T-Cell Therapy: Bijal Shah, MD; Michael Wang, MD
The hematologists from Moffitt Cancer Center and MD Anderson Cancer Center discussed the need for collaboration between academic and community practices for patients who receive CAR T-cell therapy.
Challenges in Managing High-Risk Mantle Cell Lymphoma: Bijal Shah, MD; Michael Wang, MD
The hematologist from Moffitt Cancer Center and MD Anderson Cancer Center discussed CAR T-cell therapy and other treatment options for MCL.
Insights into Brexucabtagene Autoleucel R/R B-ALL Approval: Bijal Shah, MD
The hematologist from Moffitt Cancer Center discussed the FDA approval of brexucabtagene autoleucel in relapsed/refractory B-cell acute lymphoblastic leukemia.
FDA Approval of Brexucabtagene Autoleucel for B-Cell ALL: Bijal Shah, MD, MS
The hematologist from Moffitt Cancer Center discussed the FDA approval of brexucabtagne autoleucel in relapsed/refractory B-cell acute lymphoblastic leukemia.
Brexucabtagne Autoleucel's Efficacy in ALL: Bijal Shah, MD, MS
The associate member in the Department of Malignant Hematology at Moffitt Cancer Center discussed results of the ZUMA-3 trial.
The Potential of CAR T-Cell Therapy in Adult ALL
Eunice Wang, MD, and Bijal Shah, MD, MS, discussed unmet needs for adult patients with relapsed/refractory ALL and reflect on the current treatment landscape.
The Use of Clinical Endpoints in the ZUMA-3 Trial
Bijal Shah, MD, MS, and Eunice Wang, MD, discussed the use of clinical endpoints like CR, CRi, and CRh as they relate to the ZUMA-3 trial of CAR T cell therapy.
The Importance of Timing With CAR T-Cell Therapy: Bijal Shah, MD, MS
The hematologist from Moffitt Cancer Center discussed the timing of treatment with chimeric antigen receptor T-cell therapy in patients with acute lymphoblastic leukemia.
Safety and Efficacy of the ZUMA-3 Trial
Bijal Shah, MD, MS, and Eunice Wang, MD, discuss efficacy results of the ZUMA-3 trial of chimeric antigen receptor (CAR) T-cell therapy for acute lymphocytic leukemia (ALL), and review key safety data.
ZUMA Trial of CAR T-Cell Therapy in R/R ALL
Eunice Wang, MD, and Bijal Shah, MD, MS, discuss the overall study design and patient population of the ZUMA-3 trial of CAR T-cell therapy in adult patients with R/R ALL.
Using MRD to Monitor CAR T Response in ALL
Eunice Wang, MD, and Bijal Shah, MD, MS, discussed the use of MRD status to assess therapeutic response and guide treatment decisions in patients with relapsed/refractory ALL.
The Role of CAR-T in the ALL Treatment Landscape
Eunice Wang, MD and Bijal Shah, MD, MS, discuss novel agents and emerging therapeutic approaches for the treatment of acute lymphoblastic leukemia.
Bijal D. Shah, MD, on CAR T-cell therapy and mantle cell lymphoma
Bijal D. Shah, MD, discusses the progress made regarding CAR T-cell therapy and mantle cell lymphoma.
Dr. Shah on the Use of Tisagenlecleucel in Pediatric ALL
Bijal D. Shah, MD, associate professor, Department of Malignant Hematology, Moffitt Cancer Center, discusses the use of CAR T-cell therapy in patients with pediatric acute lymphoblastic leukemia (ALL).
Dr. Shah on Challenges of CAR T-Cell Clinical Trials in MCL
Bijal D. Shah, MD, medical oncologist, Moffitt Cancer Center, assistant professor of oncology, University of South Florida, discusses the challenges of developing clinical trials for CAR T cells in mantle cell lymphoma.
Dr. Shah on the Importance of CAR T-Cell Therapy for ALL
Bijal D. Shah, MD, medical oncology, Moffit Cancer Center, discusses the importance of chimeric antigen receptor (CAR) T-cell therapy for patients with acute lymphoblastic leukemia (ALL).
Dr. Shah on Toxicites Associated With CAR T-Cell Therapy
Bijal D. Shah, MD, medical oncologist, Moffitt Cancer Center, comments on the toxicities associated with using chimeric antigen receptor (CAR) T-cell therapy in patients with leukemia.
Dr. Shah on CAR T-cell Therapy's Effectiveness in ALL
Bijal D. Shah, MD, medical oncology, of Moffit Cancer Center, explains why chimeric antigen receptor (CAR) T-cell therapy has shown the most progress in acute lymphoblastic leukemia (ALL).
Dr. Shah on Status of CAR T-cell Therapies in ALL
Bijal D. Shah, MD, medical oncology, of Moffit Cancer Center, discusses the status of chimeric antigen receptor (CAR) T-cell therapy in acute lymphoblastic leukemia (ALL).